Optimized production and concentration of lentiviral vectors containing large inserts

被引:104
作者
Al Yacoub, Nadya [1 ]
Romanowska, Malgorzata [1 ]
Haritonova, Natalie [1 ]
Foerster, John [1 ]
机构
[1] Charite, Dept Dermatol, Berlin, Germany
关键词
lentivirus; ultracentrifugation; titer; virus production;
D O I
10.1002/jgm.1052
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Generation of high titer lentiviral stocks and efficient virus concentration are central to maximize the utility of lentiviral technology. Here we evaluate published protocols for lentivirus production on a range of transfer vectors differing in size (7.5-13.2 kb). We present a modified virus production protocol robustly yielding useful titers (Up to 10(7)/ml) for a range of different transfer vectors containing packaging inserts up to 7.5 kb. Moreover, we find that virus recovery after concentration by ultracentrifugation depends on the size of the packaged inserts, heavily decreasing for large packaged inserts. We describe a fast (4 h) centrifugation protocol at reduced speed allowing high virus recovery even for large and fragile lentivirus vectors. The protocols outlined in the current report should be useful for many labs interested in producing and concentrating high titer lentiviral stocks. Copyright (C) 2007 John Wiley & Sons, Ltd.
引用
收藏
页码:579 / 584
页数:6
相关论文
共 27 条
[11]   Systematic determination of the packaging limit of lentiviral vectors [J].
Kumar, M ;
Keller, B ;
Makalou, N ;
Sutton, RE .
HUMAN GENE THERAPY, 2001, 12 (15) :1893-1905
[12]   Factors influencing the titer and infectivity of lentiviral vectors [J].
Logan, AC ;
Nightingale, SJ ;
Haas, DL ;
Cho, GJ ;
Pepper, KA ;
Kohn, DB .
HUMAN GENE THERAPY, 2004, 15 (10) :976-988
[13]   Retroviruses as tools to study the immune system [J].
Lois, C ;
Refaeli, Y ;
Qin, XF ;
Van Parijs, L .
CURRENT OPINION IN IMMUNOLOGY, 2001, 13 (04) :496-504
[14]   Lentiviral vectors and antiretroviral intrinsic immunity [J].
Mangeat, B ;
Trono, D .
HUMAN GENE THERAPY, 2005, 16 (08) :913-920
[15]   Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles [J].
Mitta, B ;
Rimann, M ;
Fussenegger, M .
METABOLIC ENGINEERING, 2005, 7 (5-6) :426-436
[16]   Metabolic biotinylation of lentiviral pseudotypes for scalable paramagnetic microparticle-dependent manipulation [J].
Nesbeth, D ;
Williams, SL ;
Chan, L ;
Brain, T ;
Slater, NKH ;
Farzaneh, F ;
Darling, D .
MOLECULAR THERAPY, 2006, 13 (04) :814-822
[17]   Generation of a packaging cell tine for prolonged large-scale production of high-titer HIV-1-based lentiviral vector [J].
Ni, YJ ;
Sun, SS ;
Oparaocha, T ;
Humeau, L ;
Davis, B ;
Cohen, R ;
Binder, G ;
Chang, YN ;
Slepushkin, V ;
Dropulic, B .
JOURNAL OF GENE MEDICINE, 2005, 7 (06) :818-834
[18]   An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins [J].
Pacchia, AL ;
Adelson, ME ;
Kaul, M ;
Ron, Y ;
Dougherty, JP .
VIROLOGY, 2001, 282 (01) :77-86
[19]   Production and concentration of pseudotyped HIV-1-based gene transfer vectors [J].
Reiser, J .
GENE THERAPY, 2000, 7 (11) :910-913
[20]   A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference [J].
Rubinson, DA ;
Dillon, CP ;
Kwiatkowski, AV ;
Sievers, C ;
Yang, LL ;
Kopinja, J ;
Zhang, MD ;
McManus, MT ;
Gertler, FB ;
Scott, ML ;
Van Parijs, L .
NATURE GENETICS, 2003, 33 (03) :401-406